Mirabegron Zentiva (Mirabegron)

Mirabegron selectively stimulates β3‑adrenergic receptors in the bladder’s detrusor muscle. This activation relaxes the muscle, allowing the bladder to hold more urine and reducing involuntary contractions that cause urgency and leakage.

The dose of mirabegron is individualized by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule.

Safety data for mirabegron during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) than antimuscarinic drugs. It does not carry the anticholinergic side‑effects such as dry mouth and constipation, and may be used alone or in combination with antimuscarinics for patients who need additional symptom control.

Store the product at room temperature, below 25 °C, in the original packaging. Protect it from moisture, excessive heat and direct sunlight to maintain stability and potency.

Mirabegron Zentiva is taken orally, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe hypertension, urinary retention, tachycardia, angioedema, myocardial infarction and anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with significant cardiovascular disease.